UNSATURATED FATTY ACID MONOESTERS AND DIESTERS ON ASCORBIC ACID AND COSMETIC USES THEREOF

La présente invention concerne un composé de formule générale (I) suivante : dans laquelle : R1 représente une chaîne hydrocarbonée d'un acide gras insaturé de C12 à C24 comprenant au moins une insaturation; et R2 et R3 représentent indépendamment ou simultanément : un Hydrogène ou un C1-C3 alkyle ou un Phényle; et R4 : un atome d'hydrogène ou COR1', avec R1' représente une chaîne hydrocarbonée d'un acide gras insaturé de C12 à C24 comprenant au moins une insaturation, avantageusement 1 à 6, et de préférence 1 à 4.

L-SERINE TO BE USED AS A DRUG FOR PREVENTING AND/OR TREATING AN INFLAMMATORY RESPONSE OF THE SKIN

L'invention concerne l'utilisation de la L-Sérine en tant que médicament pour prévenir et/ou au traiter une réaction inflammatoire de la peau provoquée par une surexpression et/ou une suractivation des récepteurs PAR2.

L-serine to be used as a drug for preventing and/or treating an inflammatory response of the skin

The invention relates to the use of L-serine as a drug for preventing and/or treating an inflammatory response of the skin caused by the overexpression and/or the overactivation of PAR2 receptors.

L-SERINE TO BE USED AS A DRUG FOR PREVENTING AND/OR TREATING AN INFLAMMATORY RESPONSE OF THE SKIN

L'invention concerne l'utilisation de la L-Sérine en tant que médicament pour prévenir et/ou au traiter une réaction inflammatoire de la peau provoquée par une surexpression et/ou une suractivation des récepteurs PAR2.

L-serine to be used as a drug for preventing and/or treating an inflammatory response of the skin

The invention relates to the use of L-serine as a drug for preventing and/or treating an inflammatory response of the skin caused by the overexpression and/or the overactivation of PAR2 receptors.

L-serine to be used as a drug for preventing and/or treating an inflammatory response of the skin

The invention relates to the use of L-serine as a drug for preventing and/or treating an inflammatory response of the skin caused by the overexpression and/or the overactivation of PAR2 receptors.

MONO ESTERS ET BIS ESTERS D'ACIDE GRAS INSATURE SUR L'ACIDE ASCORBIQUE ET LEURS UTILISATIONS COSMETIQUES

La présente invention concerne un composé de formule générale (I) suivante: dans laquelle : • R1 représente une chaîne hydrocarbonée d'un acide gras insaturé de C12 à C24 comprenant au moins une insaturation, et • R2 et R3 représentent indépendamment ou simultanément : un hydrogène ou un C1-C3 alkyle ou un phényle; et • R4 : un atome d'hydrogène ou COR1', avec R1' représente une chaîne hydrocarbonée d'un acide gras insaturé de C12 à C24 comprenant au moins une insaturation, avantageusement 1 à 6, et de préférence 1 à 4.

L-SERINE POUR SON UTILISATION EN TANT QUE MEDICAMENT POUR PREVENIR ET/OU TRAITER UNE REACTION INFLAMMATOIRE DE LA PEAU

L'invention concerne l'utilisation de la L-Sérine en tant que médicament pour prévenir et/ou traiter une réaction inflammatoire de la peau provoquée par une surexpression et/ou une suractivation des récepteurs PAR2.

UNSATURATED FATTY ACID MONOESTERS AND DIESTERS ON ASCORBIC ACID AND COSMETIC USES THEREOF

UNSATURATED FATTY ACID MONOESTERS AND DIESTERS ON ASCORBIC ACID AND COSMETIC USES THEREOF

The present invention relates to a compound with the following general formula (I): in which: R1 is a hydrocarbon chain of an unsaturated fatty acid from C12 to C24 including at least one unsaturation; and R2 and R3 are, independently or simultaneously: a hydrogen or a C1-C3 alkyl or a phenyl; and R4: a hydrogen atom or COR1, where R1 is a hydrocarbon chain of an unsaturated fatty acid from C12 to C24 including at least one unsaturation, advantageously 1 to 6 and preferably 1 to 4.

Unsaturated fatty acid monoesters and diesters on ascorbic acid and cosmetic uses thereof

The present invention relates to a compound with the following general formula (I): in which: R1 is a hydrocarbon chain of an unsaturated fatty acid from C12 to C24 including at least one unsaturation; and R2 and R3 are, independently or simultaneously: a hydrogen or a C1-C3 alkyl or a phenyl; and R4: a hydrogen atom or COR1, where R1 is a hydrocarbon chain of an unsaturated fatty acid from C12 to C24 including at least one unsaturation, advantageously 1 to 6 and preferably 1 to 4.

L-SERINE TO BE USED AS A DRUG FOR PREVENTING AND/OR TREATING AN INFLAMMATORY RESPONSE OF THE SKIN

The invention relates to the use of L-serine as a drug for preventing and/or treating an inflammatory response of the skin caused by the overexpression and/or the overactivation of PAR2 receptors.

PREPARATION CREATED FROM AN IN VITRO CULTURE OF DEDIFFERENTIATED, NON-ELICITED CELLS OF THE ARGANIA TREE, USE THEREOF FOR TREATING SKIN AGEING, INFLAMMATION AND SCARRING, AND PRODUCTION THEREOF

The invention relates to a preparation created from an in vitro culture of dedifferentiated, non-elicited cells of the Argania tree.

NOVEL BACTERIUM AND EXTRACTS OF SAID BACTERIUM AND THE USE OF SAME IN THERAPY

The present invention relates to a novel bacterial strain isolated and characterized from groundwater. The invention also relates to bacterial extracts and to the therapeutic use of same, notably in the context of the treatment of inflammations. 1. Bacterial extract obtained from a suspension of bacteria , wherein said bacteria of the suspension is a nonpathogenic Gram-negative bacterium belonging to the class Betaproteobacteria , subfamily Neisseriaceae , and characterized in that a nucleotide sequence of a 16S rRNA gene of said bacterium includes sequence SEQ ID NO: 1.2. Bacterial extract according to claim 1 , wherein said bacterium includes at least one plasmid comprising sequence SEQ ID NO: 2 claim 1 , or any sequence with at least 80% identity with said sequence SEQ ID NO: 2.3. Bacterial extract according to claim 1 , wherein said bacterium is the bacterium deposited with the CNCM on Apr. 8 claim 1 , 2010 claim 1 , under the reference 1-4290 claim 1 , or any other mutant of said bacterium.4. Bacterial extract according to claim 1 , wherein it is obtained after treatment of said bacterial suspension in such a way as to eliminate intracellular components.5. Bacterial extract according to claim 4 , wherein said intracellular components include at least nucleic acids.6. Bacterial extract according to claim 4 , wherein it includes a fraction E0 comprising at least membrane proteins claim 4 , periplasmic proteins and proteins arising from the flagellum.7. Bacterial extract according to claim 6 , wherein said membrane proteins consist of porins claim 6 , OmpA claim 6 , lipopolysaccharides and/or lipoproteins.8. Bacterial extract according to claim 4 , wherein it includes a fraction SO comprising at least secreted peptides and proteins and secondary metabolites.9. Bacterial extract according to claim 4 , wherein it includes a fraction ES0 comprising at least fraction E0 and fraction SO.10. Bacterial extract according to claim 9 , wherein said fraction ES0 has a ...

NOVEL BACTERIUM AND EXTRACTS OF SAID BACTERIUM AND THE USE OF SAME IN DERMATOLOGY

The present invention relates to a novel bacterial strain isolated from groundwater. The invention also relates to bacterial extracts and to the use of same in the context of the treatment of inflammations. More particularly, the present invention relates to novel compositions of interest in the treatment and the prevention of inflammatory disorders, notably dermatological pathologies. 1. Nonpathogenic Gram-negative bacterium belonging to the class of Betaproteobacteria , subfamily of Neisseriaceae , characterized in that the nucleotide sequence of the 16S rRNA gene of said bacterium includes sequence SEQ ID No. 1.2. The bacterium according to claim 1 , characterized in that it includes at least one plasmid comprising sequence SEQ ID No. 2 claim 1 , or any sequence with at least 80% identity with said sequence SEQ ID No. 2.3. The bacterium according to claim 1 , characterized in that it is nonfilamentous.4. The bacterium according to claim 1 , deposited with the CNCM on Apr. 8 claim 1 , 2010 claim 1 , under the reference 1-4290.5. A bacterial extract obtained from a suspension of bacteria according to .6. The bacterial extract according to claim 5 , characterized in that it is obtained after treatment of said bacterial suspension in such a way as to eliminate the intracellular components.7. The bacterial extract according to claim 6 , characterized in that said intracellular components include at least nucleic acids.8. The bacterial extract according to claim 6 , characterized in that it includes a fraction E0 comprising at least membrane proteins claim 6 , periplasmic proteins and proteins arising from the flagellum.9. The bacterial extract according to claim 8 , characterized in that said membrane proteins consist of porins claim 8 , OmpA claim 8 , lipopolysaccharides and/or lipoproteins.10. The bacterial extract according to claim 6 , characterized in that it includes a fraction S0 comprising at least secreted peptides and proteins and secondary metabolites.11. ...

BACTERIAL SECRETOME FOR USE IN THE TREATMENT OF SKIN LESIONS

The present invention relates to a novel use of a bacterial secretome in the field of the treatment of skin lesions and more particularly of wound healing. The invention also relates to cosmetic or dermatological compositions comprising such a bacterial secretome as active agent. 1. A method of treatment of skin lesions which comprises administering to a patient in need thereof a bacterial secretome of a non-pathogenic Gram-negative bacterium belonging to the class Betaproteobacteria , subfamily Neisseriaceae , containing a 16S rRNA comprising sequence SEQ ID No. 1 , or any sequence having at least 80% identity with sequence SEQ ID No. 1 , whereinsaid secretome is obtained by a process comprising the steps of:a) culturing said bacterium in a culture medium and under conditions suitable for its growth,b) liquid/solid separation and recovery of the liquid phase,c) obtaining said secretome comprising biomolecules secreted by said bacterium in the liquid phase.2. The method according to claim 1 , wherein a basic buffer is added to the liquid phase obtained in step b) and that the buffered liquid phase obtained is optionally left in contact for 1 to 7 h claim 1 , preferably at a temperature between 1 and 6° C.3. The method according to claim 2 , wherein the basic buffer is selected from Tris buffer claim 2 , arginine buffer and mixtures thereof.4. The method according to claim 1 , wherein step b) of liquid/solid separation is followed by a step b′) of clarification of the liquid phase or of the buffered liquid phase by filtration before step c).5. The method according to claim 4 , wherein the filtration is performed with a 0.2 μm cut-off.6. The method according to claim 1 , wherein said biomolecules comprise peptides claim 1 , proteins and secondary metabolites secreted by said bacterium.7. The method according to claim 1 , wherein the bacterium contains at least one plasmid comprising sequence SEQ ID No. 2 claim 1 , or any sequence having at least 80% identity with ...

COMBINATION OF A RETINOID AND A DIOL AND POLYUNSATURATED FATTY ACID ESTER

The present invention concerns a combination of a retinoid and a diol and polyunsaturated fatty acid ester, a dermatological or dermocosmetic composition containing such a combination and use of same in the treatment of acne and the prevention of retentional lesions. The present invention also concerns a retinoid, optionally in combination with a diol and polyunsaturated fatty acid ester, for use in the prevention of retentional lesions. 118-. (canceled)20. The combination according to claim 19 , wherein n is between 1 and 10.21. The combination according to claim 20 , wherein n is 1 claim 20 , 2 claim 20 , 3 claim 20 , 4 or 5.22. The combination according to claim 19 , wherein m is 0 or 1.23. The combination according to claim 19 , wherein the polyunsaturated fatty acid is selected from α-linolenic acid claim 19 , stearidonic acid claim 19 , eicosatrienoic acid claim 19 , eicosatetraenoic acid claim 19 , eicosapentaenoic acid claim 19 , docosapentaenoic acid claim 19 , docosahexaenoic acid claim 19 , tetracosapentaenoic acid claim 19 , tetracosahexaenoic acid claim 19 , linoleic acid claim 19 , gamma-linolenic acid claim 19 , eicosadienoic acid claim 19 , dihomo-gamma-linolenic acid claim 19 , arachidonic acid claim 19 , docosatetraenoic acid claim 19 , docosapentaenoic acid claim 19 , adrenic acid and calendic acid.24. The combination according to claim 23 , wherein the polyunsaturated fatty acid is α-linolenic acid claim 23 , stearidonic acid or linoleic acid.26. The combination according to claim 19 , wherein the retinoid is selected from retinol claim 19 , retinaldehyde claim 19 , and retinoic acid in its various stereoisomeric forms.28. A method for preventing the formation of retentional lesions or for treating acne comprising the administration to a patient in need thereof of an effective amount of a combination according to .29. A dermatological or dermocosmetic composition comprising at least one combination according to in association with at least one ...

NOVEL BACTERIUM AND EXTRACTS OF SAID BACTERIUM AND THE USE OF SAME IN DERMATOLOGY

The present invention relates to a novel bacterial strain isolated from groundwater. The invention also relates to bacterial extracts and to the use of same in the context of the treatment of inflammations. More particularly, the present invention relates to novel compositions of interest in the treatment and the prevention of inflammatory disorders, notably dermatological pathologies. 1. A bacterial extract obtained after treatment of a bacterial suspension in such a way as to eliminate the intracellular components from said bacterial suspension , wherein said bacterial suspension is a suspension of a Gram-negative bacterium belonging to the class of Betaproteobacteria , subfamily of Neisseriaceae which nucleotide sequence of the 16S rRNA gene includes sequence SEQ ID No. 1.2. The bacterial extract according to claim 1 , wherein said bacterium includes at least one plasmid comprising sequence SEQ ID No. 2 claim 1 , or any sequence with at least 80% identity with said sequence SEQ ID No. 2.3. The bacterial extract according to claim 1 , wherein said bacterium is nonfilamentous.4. The bacterial extract according to claim 1 , wherein said bacterium is deposited within the CNCM on Apr. 8 claim 1 , 2010 claim 1 , under the reference 1-4290.5. The bacterial extract according to claim 1 , wherein said intracellular components include at least nucleic acids.6. The bacterial extract according to claim 1 , characterized in that it includes a fraction E0 comprising at least membrane proteins claim 1 , periplasmic proteins and proteins arising from the flagellum.7. The bacterial extract according to claim 6 , wherein said membrane proteins consist of porins claim 6 , OmpA claim 6 , lipopolysaccharides and/or lipoproteins.8. The bacterial extract according to claim 1 , characterized in that it includes a fraction S0 comprising at least secreted peptides and proteins and secondary metabolites.9. The bacterial extract according to claim 1 , characterized in that it includes a ...

EXTRACT AND DERMATOLOGICAL COMPOSITION COMPRISING SAME, FOR TREATING SENSITIVE SKIN

The invention relates to a new bacterial extract that can be used for protecting and/or treating sensitive skin and/or reactive, intolerant skin, particularly by means of targeted action on neurogenic inflammation of the skin. The invention also relates to cosmetic or dermatological compositions comprising such a bacterial extract as an active ingredient. 1. Bacterial extract of a non-pathogenic Gram-negative bacterium belonging to the class Betaproteobacteria , subfamily Neisseriaceae , comprising a 16S rRNA comprising sequence SEQ ID NO: 1 , or any sequence having at least 80% identity with sequence SEQ ID NO: 1 , said bacterial extract being obtained by a process comprising the steps of:a. culture of said bacterium in a suitable medium to obtain a bacterial culture;b. liquid phase/solid phase separation of said bacterial culture and removal of the liquid phase;c. cell lysis of the solid phase,d. resuspension of the lysed solid phase in an aqueous liquid phase,e. liquid phase/solid phase separation and recovery of the liquid phase,f. optional filtration of the liquid phase.2. Bacterial extract according to claim 1 , wherein the aqueous liquid phase of the resuspension step d) is a basic buffer.3. Bacterial extract according to claim 2 , wherein the basic buffer comprises at least one of Tris buffer claim 2 , arginine buffer and Tris-arginine buffer.4. Bacterial extract according to claim 1 , wherein the bacterium comprises at least one plasmid comprising sequence SEQ ID NO: 2 claim 1 , or any sequence having at least 80% identity with sequence SEQ ID NO: 2.5. Bacterial extract according to claim 1 , wherein the bacterium is LMB64 claim 1 , deposited at the CNCM on 8 April 2010 under number 1-4290.6. A method for treating cutaneous neurogenic inflammation in a person in need thereof claim 1 , comprising the administration of a bacterial extract according to .7. The method according to claim 6 , wherein the cutaneous neurogenic inflammation includes sensitive skin ...

Synergistic combination of alanine-glutamine, hyaluronic acid and oat extract and the use thereof in a composition intended for healing wounds and repairing skin lesions

The present invention concerns a combination comprising the dipeptide L-alanyl-L-glutamine, hyaluronic acid or one of the salts of same and an oat extract, advantageously intended for healing wounds and repairing skin lesions.

COSMETIC COMPOSITION COMPRISING A COMBINATION OF PONGAMIA OIL AND 4-T-BUTYLCYCLOHEXANOL FOR THE TREATMENT OF ROSACEA

The present invention relates to the novel combination of pongamia oil and 4-t-butylcyclohexanol, and to the uses thereof in the fields of cosmetics and dermatology to combat redness. 112-. (canceled)13. Method for treating rosacea or skin redness comprising the administration to a patient in need thereof , of a combination comprising pongamia oil and 4-t-butylcyclohexanol , wherein the 4-t-butylcyclohexanol is solubilized in 1 ,5-pentanediol.14. Method according to claim 13 , wherein the rosacea is selected from the group consisting of erythematotelangiectatic rosacea claim 13 , papulopustular rosacea claim 13 , phymatous rosacea claim 13 , ocular rosacea.15. Method according to claim 13 , wherein the administration is topical.16. Dermatological or dermocosmetic composition comprising a combination pongamia oil and 4-t-butylcyclohexanol claim 13 , wherein the 4-t-butylcyclohexanol is solubilized in 1 claim 13 ,5-pentanediol claim 13 , in association with at least one dermatologically or dermocosmetically acceptable excipient.17. Dermatological or dermocosmetic composition according to claim 16 , wherein it comprises 0.01 to 5 wt % claim 16 , preferably 0.05 to 2 wt % pongamia oil based on the total weight of the composition.18. Dermatological or dermocosmetic composition according to claim 16 , wherein it comprises 0.01 to 5 wt % claim 16 , preferably 0.05 to 2 wt % claim 16 , 4-t-butylcyclohexanol solubilized in 1 claim 16 ,5-pentanediol based on the total weight of the composition.19. Dermatological or dermocosmetic composition according to claim 16 , wherein it is in a form suitable for topical application. The present invention relates to the novel combination of pongamia oil and 4-t-butylcyclohexanol, and to the uses thereof in the fields of cosmetics and dermatology to combat redness.More specifically, the present invention relates to the cosmetic use of a composition comprising said combination to combat rosacea.The skin is the largest organ of the human ...

ASSOCIATION OF A RETINOID AND AN ESTER OF DIOL AND POLYUNSATURATED FATTY ACID

NOVEL BACTERIA AND EXTRACTS OF SAID BACTERIUM AND THEIR THERAPEUTIC USE

BACTERIAL SECRETOME FOR USE IN THE TREATMENT OF SKIN LESIONS

La présente invention concerne une nouvelle utilisation d'un sécrétome bactérien dans le domaine du traitement des lésions cutanées et plus particulièrement de la cicatrisation. L'invention a également pour objet des compositions cosmétiques ou dermatologiques comprenant un tel sécrétome bactérien comme agent actif. The present invention relates to a new use of a bacterial secretome in the field of the treatment of skin lesions and more particularly of cicatrization. A subject of the invention is also cosmetic or dermatological compositions comprising such a bacterial secretome as an active agent.

NOVEL BACTERIA AND EXTRACTS OF SAID BACTERIUM AND THEIR USE IN DERMATOLOGY

La présente invention a pour un objet une nouvelle souche bactérienne isolée à partir d'une nappe phréatique. L'invention concerne également des extraits bactériens et leur utilisation dans le cadre du traitement des inflammations. Plus particulièrement, la présente invention se rapporte à de nouvelles compositions intéressantes dans le traitement et dans la prévention des troubles inflammatoires notamment des pathologies dermatologiques. The present invention has for one object a new bacterial strain isolated from a water table. The invention also relates to bacterial extracts and their use in the treatment of inflammation. More particularly, the present invention relates to novel compositions of interest in the treatment and prevention of inflammatory disorders, in particular dermatological pathologies.

USE OF 4- (1-PHENYLTHYL) BENZENE-1,3-DIOL IN THE TREATMENT OF INFLAMMATORY DERMATOSES

La présente invention concerne le 4- (1-phényléthyl) benzène-1,3-diol , pour son utilisation dans la prévention et/ou le traitement de l'inflammation en particulier l'inflammation cutanée, notamment dans les dermatoses inflammatoires. The present invention relates to 4- (1-phenylethyl) benzene-1,3-diol for its use in the prevention and / or treatment of inflammation, particularly cutaneous inflammation, particularly in inflammatory dermatoses.

SYNERGISTIC ASSOCIATION OF ALANINE-GLUTAMINE, HYALURONIC ACID AND OAT EXTRACT, AND USE THEREOF IN A COMPOSITION FOR SCALING AND REPAIRING SKIN LESIONS

La présente invention concerne une association comprenant le dipeptide alanine-glutamine, l'acide hyaluronique ou un de ses sels et un extrait d'avoine, avantageusement destinée à la cicatrisation et la réparation des lésions cutanées. The present invention relates to a combination comprising the dipeptide alanine-glutamine, hyaluronic acid or a salt thereof and an oat extract, preferably for the healing and repair of cutaneous lesions.

ASSOCIATION OF A RETINOID AND AN ESTER OF DIOL AND POLYUNSATURATED FATTY ACID

La présente invention concerne une association d'un rétinoïde et d'un ester de diol et d'acide gras polyinsaturé, une composition dermatologique ou dermo-cosmétique contenant une telle association et leur utilisation dans le traitement de l'acné et dans la prévention des lésions rétentionnelles. La présente invention concerne également un rétinoïde, éventuellement en association avec un ester de diol et d'acide gras polyinsaturé, pour son utilisation dans la prévention des lésions rétentionnelles. The present invention relates to a combination of a retinoid and a diol ester and polyunsaturated fatty acid, a dermatological or dermo-cosmetic composition containing such an association and their use in the treatment of acne and in the prevention of retentional lesions. The present invention also relates to a retinoid, optionally in combination with a diol ester and polyunsaturated fatty acid, for its use in the prevention of retentional lesions.

SYNERGISTIC ASSOCIATION OF ALANINE-GLUTAMINE, HYALURONIC ACID AND OAT EXTRACT, AND USE THEREOF IN A COMPOSITION FOR SCALING AND REPAIRING SKIN LESIONS

L-SERINE AND / OR L-ASPARAGINE AND / OR L-VALINE FOR PREVENTING AND / OR TREATING INFLAMMATORY SKIN REACTIONS.

COSMETIC COMPOSITION COMPRISING AN ASSOCIATION OF PONGAMIA OIL AND PENTYLENE GLYCOL 4-T-BUTYLCYCLOHEXANOL FOR CONTROLLING ROSACEA

La présente invention concerne la nouvelle association suivante : huile de pongamia et pentylene glycol 4-t-butylcyclohexanol ; et ses applications dans les domaines de la cosmétique et de la dermatologie pour lutter contre les rougeurs. Plus particulièrement, la présente invention concerne l'utilisation cosmétique d'une composition comprenant ladite association pour lutter contre la rosacée. The present invention relates to the following new association: pongamia oil and pentylene glycol 4-t-butylcyclohexanol; and its applications in the fields of cosmetics and dermatology for combating redness. More particularly, the present invention relates to the cosmetic use of a composition comprising said combination for combating rosacea.

USE OF (2S) -2-AMINOPENTANEDIOIC ACID FOR THE TREATMENT OF SEBORRHEA

NOVEL BACTERIA AND EXTRACTS OF SAID BACTERIUM AND THEIR THERAPEUTIC USE

La présente invention a pour un objet une nouvelle souche bactérienne isolée et caractérisée à partir d'une nappe phréatique. L'invention concerne également des extraits bactériens et leur utilisation thérapeutique, notamment dans le cadre du traitement des inflammations. The present invention has for object a new bacterial strain isolated and characterized from a water table. The invention also relates to bacterial extracts and their therapeutic use, particularly in the context of the treatment of inflammations.

Novel bacterium and extracts of said bacterium and the use of same in dermatology

The present invention relates to a novel bacterial strain isolated from groundwater. The invention also relates to bacterial extracts and to the use of same in the context of the treatment of inflammations. More particularly, the present invention relates to novel compositions of interest in the treatment and the prevention of inflammatory disorders, notably dermatological pathologies.

Synergistic association of alanine-glutamine, hyaluronic acid and an oat extract and its use in a composition intended for healing and repair of skin lesions

Asociación que comprende L-alanil-L-glutamina, ácido hialurónico o una de sus sales y un extracto de avena. Association comprising L-alanyl-L-glutamine, hyaluronic acid or one of its salts and an oat extract.

Synergistic combination of alanine-glutamine, hyaluronic acid and an oat extract and the use thereof in a composition intended for healing wounds and repairing skin lesions

Combination of a retinoid and a diol and polyunsaturated fatty acid ester.

La presente invención se refiere a una combinación de un retinoide y un diol y éster de ácidos grasos poliinsaturados, a una composición dermatológica o dermocosmética que contiene tal combinación y el uso de la misma en el tratamiento contra el acné y para prevenir lesiones retencionales. La presente invención también se refiere a un retinoide, opcionalmente combinado con un diol y un éster de ácidos grasos poliinsaturados, para su uso en la prevención de lesiones retencionales.

Novel bacterium and extracts of said bacterium and the use of same in therapy

The present invention relates to a novel bacterial strain isolated and characterized from groundwater. The invention also relates to bacterial extracts and to the therapeutic use of same, notably in the context of the treatment of inflammations.

PREPARATION FROM IN VITRO CULTURE OF NON-ELICITED ARGANIER DIFFERENTIAL CELLS, USE THEREOF FOR THE TREATMENT OF SKIN AGING, INFLAMMATION AND HEALING, AND OBTAINING THEM.

L-SERINE AND / OR L-ASPARAGINE AND / OR L-VALINE FOR PREVENTING AND / OR TREATING INFLAMMATORY SKIN REACTIONS.

L'invention concerne l'utilisation de la L-Sérine et/ou de la L-Asparagine et/ou L-Valine pour prévenir et/ou au traiter des réactions inflammatoires de la peau provoquées par une surexpression et/ou une suractivation des récepteurs PAR2.

Topical composition containing a combination of at least one blue algae extract with at least one alpha hydroxy acid or one of the salts thereof

The invention relates to the combination of at least one blue algae extract and at least one alpha hydroxyl acid or one of the salts thereof in a topical composition. The invention also relates to the use, in particular the topical use, of the above-mentioned active agents, singly or in combination with each other, to promote VEGF production for the use thereof in the revascularization of the epidermis, to promote natural production of collagen, elastin fibers, and hyaluronic acid, and to use said active agents as an antioxidant and to prevent signs of aging in the organism.

COSMETIC COMPOSITION COMPRISING PONGAMIA OIL AND 4-T-BUTYLCYCLOHEXANOL AND USES TO TREAT CUTANEOUS REDNESS OR ROSACEA

A presente invenção refere-se à nova associação a seguir: óleo de pongamia e 4-t-butilciclohexanol e suas aplicações nos campos da cosmética e da dermatologia para combater as vermelhidões da pele. Mais especificamente, a presente invenção refere-se à utilização cosmética de uma composição que compreende a dita associação para combater a rosácea. The present invention relates to the following new combination: pongamia oil and 4-t-butylcyclohexanol and its applications in the fields of cosmetics and dermatology to combat skin redness. More specifically, the present invention relates to the cosmetic use of a composition comprising said association to combat rosacea.

TOPICAL COMPOSITION COMPRISING AN ASSOCIATION OF AT LEAST ONE BLUE ALGAE EXTRACT WITH AT LEAST ONE ALPHA HYDROXYL ACID OR ONE OF ITS SALTS

Use of (2S)-2-aminopentanoic acid in a composition e.g. hair care composition, preferably shampoo, hair setting lotion and styling cream or gel for treating seborrhea of skin and scalp and for slowing down hair loss

Use of (2S)-2-aminopentanoic acid for treating seborrhea, is claimed. An independent claim is included for an antiseborrhoeic composition comprising the (2S)-2-aminopentanoic acid and a support. ACTIVITY : Antiseborrheic; Dermatological; Endocrine-Gen. MECHANISM OF ACTION : 5 Alpha-reductase inhibitor. The ability of (2S)-2-aminopentanoic acid to inhibit the expression of 5 alpha-reductase type I was tested in dermal papilla cell. The result showed that the (2S)-2-aminopentanoic acid exhibited a percentage inhibition of 17 at a concentration of 0.2 mu M.

Bacterium and extracts of said bacterium and the use of same in dermatology

The present invention relates to a novel bacterial strain isolated from groundwater. The invention also relates to bacterial extracts and to the use of same in the context of the treatment of inflammations. More particularly, the present invention relates to novel compositions of interest in the treatment and the prevention of inflammatory disorders, notably dermatological pathologies.

Extract and dermatological composition comprising same, for treating sensitive skin

The invention relates to a new bacterial extract that can be used for protecting and/or treating sensitive skin and/or reactive, intolerant skin, particularly by means of targeted action on neurogenic inflammation of the skin. The invention also relates to cosmetic or dermatological compositions comprising such a bacterial extract as an active ingredient.

Preparation created from an in vitro culture of dedifferentiated, non-elicited cells of the argania tree, use thereof for treating skin ageing, inflammation and scarring, and prod uction thereof

L'invention concerne une préparation issue d'une culture in vitro de cellules dédifférenciées non élicitées d'Arganier et son utilisation dans le traitement du vieillissement cutané, de l'inflammation et de la cicatrisation.

Cosmetic composition comprising a combination of pongamia oil and 4-t-butylcyclohexanol for the treatment of rosacea

The present invention relates to the novel combination of pongamia oil and 4-t-butylcyclohexanol, and to the uses thereof in the fields of cosmetics and dermatology for the treatment of redness of the skin. More specifically, the present invention relates to the cosmetic use of a composition comprising said combination for the treatment of rosacea.

Unsaturated fatty acid monoesters and diesters on ascorbic acid and cosmetic uses thereof

The present invention relates to a compound with the following general formula (I): in which: R 1 is a hydrocarbon chain of an unsaturated fatty acid from C 12 to C 24 including at least one unsaturation; and R 2 and R 3 are, independently or simultaneously: a hydrogen or a C 1 -C 3 alkyl or a phenyl; and R 4 : a hydrogen atom or COR 1' , where R 1' is a hydrocarbon chain of an unsaturated fatty acid from C 12 to C 24 including at least one unsaturation, advantageously 1 to 6 and preferably 1 to 4.

Use of a live bacterium for the treatment of intestinal inflammatory disorders

The present invention relates to the use of a bacterial strain isolated and characterized from groundwater, notably in the context of the treatment of inflammations. More particularly, the present invention relates to novel compositions of interest, particularly probiotic composition, in the treatment and the prevention of intestinal inflammatory disorders and to a method of treatment of intestinal inflammatory disorders.

Topical composition comprising an association of at least one blue seaweed extract with at least one alpha-hydroxylated acid or one of its salts

Composición tópica, caracterizada por que contiene por lo menos un extracto de alga azul y por lo menos una sal de ácido alfa-hidroxilado soluble en medio acuoso, seleccionada de entre las sales de magnesio, de calcio y de sodio, así como sus mezclas, en asociación con por lo menos un excipiente aceptable para la aplicación tópica. Topical composition, characterized in that it contains at least one extract of blue algae and at least one salt of alpha-hydroxylated acid soluble in aqueous medium, selected from magnesium, calcium and sodium salts, as well as mixtures thereof, in association with at least one excipient acceptable for topical application.

EXTRACT AND DERMATOLOGICAL COMPOSITION COMPRISING SAME FOR THE TREATMENT OF SENSITIVE SKIN

La présente invention concerne un nouvel extrait bactérien qui peut être utile dans la protection et/ou le traitement de la peau sensible et/ou de la peau intolérante réactive, notamment par une action ciblée sur l'inflammation neurogène cutanée. L'invention a également pour objet des compositions cosmétiques ou dermatologiques comprenant un tel extrait bactérien comme agent actif. The present invention relates to a new bacterial extract which may be useful in the protection and / or treatment of sensitive skin and / or reactive intolerant skin, in particular by a targeted action on neurogenic skin inflammation. The invention also relates to cosmetic or dermatological compositions comprising such a bacterial extract as active agent.

Extrait et composition dermatologique le comprenant pour le traitement des peaux sensibles

Extracto y composición dermatológica que lo contiene para el tratamiento de pieles sensibles

La invención se refiere a un nuevo extracto bacteriano que puede utilizarse para proteger y/o tratar la piel sensible y/o la piel reactiva e intolerante, en particular mediante una acción específica sobre la inflamación neurogénica de la piel. La invención también se refiere a composiciones cosméticas o dermatológicas que comprenden dicho extracto bacteriano como ingrediente activo. (Traducción automática con Google Translate, sin valor legal)

Extract and dermatological composition comprising same, for treating sensitive skin

The invention relates to a new bacterial extract that can be used for protecting and/or treating sensitive skin and/or reactive, intolerant skin, particularly by means of targeted action on neurogenic inflammation of the skin. The invention also relates to cosmetic or dermatological compositions comprising such a bacterial extract as an active ingredient.

Synergistic combination of alanine-glutamine, hyaluronic acid and oat extract and the use thereof in a composition intended for healing wounds and repairing skin lesions

The present invention concerns a combination comprising the dipeptide L-alanyl-L-glutamine, hyaluronic acid or one of the salts of same and an oat extract, advantageously intended for healing wounds and repairing skin lesions.

Bacterium and extracts of said bacterium and the use of same in dermatology

The present invention relates to a novel bacterial strain isolated from groundwater. The invention also relates to bacterial extracts and to the use of same in the context of the treatment of inflammations. More particularly, the present invention relates to novel compositions of interest in the treatment and the prevention of inflammatory disorders, notably dermatological pathologies.

Bacterium and extracts of said bacterium and the use of same in therapy

The present invention relates to a novel bacterial strain isolated and characterized from groundwater. The invention also relates to bacterial extracts and to the therapeutic use of same, notably in the context of the treatment of inflammations.